{"id":35888,"date":"2025-06-24T17:57:20","date_gmt":"2025-06-24T09:57:20","guid":{"rendered":"https:\/\/flcube.com\/?p=35888"},"modified":"2025-06-24T17:57:21","modified_gmt":"2025-06-24T09:57:21","slug":"cloudbreak-pharmas-ipo-raises-hkd-522m-for-ophthalmic-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35888","title":{"rendered":"Cloudbreak Pharma&#8217;s IPO Raises HKD 522M for Ophthalmic Drug Development"},"content":{"rendered":"\n<p>Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of 60.6 million shares on the Hong Kong Stock Exchange (HKEX). Priced at HKD 10.1 per share, the offering is expected to generate proceeds of approximately HKD 522 million (USD 66.5 million) for the Cayman Island-registered company. CCB International and Huatai International served as co-sponsors for the IPO.<\/p>\n\n\n\n<p><strong>Pipeline Highlights<\/strong><br>Cloudbreak Pharma&#8217;s development pipeline includes two core candidates: CBT-001 and CBT-009. CBT-001 is currently undergoing multi-regional Phase III clinical trials in both the US and China for the treatment of pterygium, a benign ocular surface disorder characterized by conjunctival overgrowth. Meanwhile, CBT-009 is being developed to address myopia in children and adolescents aged 5\u201319. This candidate completed Phase I\/II trials in 2023 and a clinical study application was filed in the US in 2024.<\/p>\n\n\n\n<p><strong>Additional Programs<\/strong><br>The company also has several other clinical-stage assets, including CBT-006 and CBT-004, along with four preclinical candidates: CBT-007, CBT-199, CBT-145, and CBT-011.<\/p>\n\n\n\n<p><strong>Financial Overview<\/strong><br>In 2024, Cloudbreak reported revenue of approximately USD 10 million. The company invested heavily in research and development, with expenditures reaching USD 37.95 million and an annual net loss of USD 99.13 million. From 2022 to 2024, cumulative R&amp;D spending amounted to USD 84.53 million, underscoring the company&#8217;s dedication to advancing its therapeutic pipeline.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025062400006_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025062400006_c.\"><\/object><a id=\"wp-block-file--media-00399c01-7a2e-4bc4-8038-5708cbe3c888\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025062400006_c.pdf\">2025062400006_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025062400006_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-00399c01-7a2e-4bc4-8038-5708cbe3c888\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35890,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[414,72,44],"class_list":["post-35888","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cloudbreak-pharma","tag-ipo","tag-ophthalmology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cloudbreak Pharma&#039;s IPO Raises HKD 522M for Ophthalmic Drug Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of 60.6 million shares on the Hong Kong Stock Exchange (HKEX). Priced at HKD 10.1 per share, the offering is expected to generate proceeds of approximately HKD 522 million (USD 66.5 million) for the Cayman Island-registered company. CCB International and Huatai International served as co-sponsors for the IPO.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35888\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cloudbreak Pharma&#039;s IPO Raises HKD 522M for Ophthalmic Drug Development\" \/>\n<meta property=\"og:description\" content=\"Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of 60.6 million shares on the Hong Kong Stock Exchange (HKEX). Priced at HKD 10.1 per share, the offering is expected to generate proceeds of approximately HKD 522 million (USD 66.5 million) for the Cayman Island-registered company. CCB International and Huatai International served as co-sponsors for the IPO.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35888\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-24T09:57:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T09:57:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35888#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35888\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cloudbreak Pharma&#8217;s IPO Raises HKD 522M for Ophthalmic Drug Development\",\"datePublished\":\"2025-06-24T09:57:20+00:00\",\"dateModified\":\"2025-06-24T09:57:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35888\"},\"wordCount\":226,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35888#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2405.webp\",\"keywords\":[\"Cloudbreak Pharma\",\"IPO\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35888#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35888\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35888\",\"name\":\"Cloudbreak Pharma's IPO Raises HKD 522M for Ophthalmic Drug Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35888#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35888#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2405.webp\",\"datePublished\":\"2025-06-24T09:57:20+00:00\",\"dateModified\":\"2025-06-24T09:57:21+00:00\",\"description\":\"Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of 60.6 million shares on the Hong Kong Stock Exchange (HKEX). Priced at HKD 10.1 per share, the offering is expected to generate proceeds of approximately HKD 522 million (USD 66.5 million) for the Cayman Island-registered company. CCB International and Huatai International served as co-sponsors for the IPO.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35888#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35888\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35888#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2405.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2405.webp\",\"width\":1080,\"height\":608,\"caption\":\"Cloudbreak Pharma's IPO Raises HKD 522M for Ophthalmic Drug Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35888#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cloudbreak Pharma&#8217;s IPO Raises HKD 522M for Ophthalmic Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cloudbreak Pharma's IPO Raises HKD 522M for Ophthalmic Drug Development - Insight, China&#039;s Pharmaceutical Industry","description":"Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of 60.6 million shares on the Hong Kong Stock Exchange (HKEX). Priced at HKD 10.1 per share, the offering is expected to generate proceeds of approximately HKD 522 million (USD 66.5 million) for the Cayman Island-registered company. CCB International and Huatai International served as co-sponsors for the IPO.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35888","og_locale":"en_US","og_type":"article","og_title":"Cloudbreak Pharma's IPO Raises HKD 522M for Ophthalmic Drug Development","og_description":"Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of 60.6 million shares on the Hong Kong Stock Exchange (HKEX). Priced at HKD 10.1 per share, the offering is expected to generate proceeds of approximately HKD 522 million (USD 66.5 million) for the Cayman Island-registered company. CCB International and Huatai International served as co-sponsors for the IPO.","og_url":"https:\/\/flcube.com\/?p=35888","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-24T09:57:20+00:00","article_modified_time":"2025-06-24T09:57:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35888#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35888"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cloudbreak Pharma&#8217;s IPO Raises HKD 522M for Ophthalmic Drug Development","datePublished":"2025-06-24T09:57:20+00:00","dateModified":"2025-06-24T09:57:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35888"},"wordCount":226,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35888#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405.webp","keywords":["Cloudbreak Pharma","IPO","Ophthalmology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35888#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35888","url":"https:\/\/flcube.com\/?p=35888","name":"Cloudbreak Pharma's IPO Raises HKD 522M for Ophthalmic Drug Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35888#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35888#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405.webp","datePublished":"2025-06-24T09:57:20+00:00","dateModified":"2025-06-24T09:57:21+00:00","description":"Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of 60.6 million shares on the Hong Kong Stock Exchange (HKEX). Priced at HKD 10.1 per share, the offering is expected to generate proceeds of approximately HKD 522 million (USD 66.5 million) for the Cayman Island-registered company. CCB International and Huatai International served as co-sponsors for the IPO.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35888#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35888"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35888#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405.webp","width":1080,"height":608,"caption":"Cloudbreak Pharma's IPO Raises HKD 522M for Ophthalmic Drug Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35888#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cloudbreak Pharma&#8217;s IPO Raises HKD 522M for Ophthalmic Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2405.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35888"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35888\/revisions"}],"predecessor-version":[{"id":35891,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35888\/revisions\/35891"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35890"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}